Targeting of acivicin prodrugs as antibody conjugates

J Control Release. 2001 Jul 6;74(1-3):255-7. doi: 10.1016/s0168-3659(01)00327-3.

Abstract

The ectopeptidase gamma-glutamyltranspeptidase (gamma-GT) is overexpressed in myeloid leukemias. Its specific inhibitor, acivicin, was previously shown to induce an inhibitory growth effect associated with an induction of morphological features characteristic of macrophage maturation. We have considered a construction in which an antibody linked to a prodrug of acivicin will target acivicin to tumoral cells. In a first set of experiments we have synthesized a chromogenic model of this prodrug to validate this concept of prodrug, allowing an amine function to be released upon esterase action. Thereafter this model was applied to acivicin. The acivicin prodrug is inactive toward purified gamma-GT, and recovers its inhibitory activity under the effect of esterase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / chemistry
  • Antibiotics, Antineoplastic / pharmacokinetics*
  • Carbamates / chemistry
  • Esterases / chemistry
  • Hydrolysis
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / chemistry
  • Immunoconjugates / pharmacokinetics*
  • Isoxazoles / administration & dosage*
  • Isoxazoles / chemistry
  • Isoxazoles / pharmacokinetics*
  • Models, Chemical
  • Prodrugs* / chemistry
  • Spectrophotometry, Ultraviolet
  • gamma-Glutamyltransferase / chemistry*

Substances

  • Antibiotics, Antineoplastic
  • Carbamates
  • Immunoconjugates
  • Isoxazoles
  • Prodrugs
  • gamma-Glutamyltransferase
  • Esterases
  • acivicin